Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Guggenheim analyst Vamil Divan initiates coverage on ProKidney (NASDAQ:PROK) with a Buy rating and announces Price Target of...
B of A Securities analyst Jason Gerberry maintains ProKidney (NASDAQ:PROK) with a Neutral and lowers the price target from $...
The Company believes rilparencel is eligible for initial FDA approval under an expedited approval pathway based upon successful...
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.17) by ...
All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold...
